Alzheimer's Disease Biomarker Assay Heading for IVD Status
|
By LabMedica International staff writers Posted on 24 Jul 2017 |
|
Image: A structural representation of the ApoE protein from human blood plasma (Photo courtesy of Wikimedia Commons).
A clinical diagnostic kit that measures the concentration of the Alzheimer's disease blood biomarker APOEepsilon4 was unveiled at the Alzheimer’s Association Conference held in London, United Kingdom, from July 16-20, 2017.
The risk of developing Alzheimer’s disease (AD) is increased by three to five-folds with the presence of one epsilon4 allele and between 15 and 20 times with two alleles.
The frequency of the epsilon4 allele is approximately 40% in patients with AD. Furthermore, APOEepsilon4 carriers progress faster to clinical AD than do APOEepsilon4 non-carriers. Therefore, the presence of one or two epsilon4 alleles of the APOE gene is considered to be highly informative in epidemiological research and is currently being used for patient stratification in the latest clinical trials to evaluate AD treatments.
The Biocross (Valladolid, Spain) ApoE4 Blood Marker Assay is an immunoturbidimetry-based test. Each assay kit consists of two reagents: R1 (which contains a highly specific anti-apoE4 antibody) and R2 (a solution containing latex (polystyrene beads). During the assay, the anti-apoE4 antibody induces the agglutination of latex beads in the presence of apoE4 in the sample. This agglutination is proportional to the concentration of the apoE4 and can be measured manually or automatically with a spectrophotometer.
The ApoE4 Blood Marker Assay can be used with manageable cost in any of the clinical biochemistry analyzers that are available in most hospitals or clinical centers. The risk indicator is determined by a cost-effective and accurate blood test that is scheduled to obtain the European IVD CE mark and will be submitted for [U.S.] Food and Drug Administration approval by the end of the year.
Matthew Mittino, CEO of Biocross, said, “Introducing our risk test ApoE4 Blood Marker Assay to experts, researchers, physicians, neurologists, and specialists in neurodegenerative diseases from more than 70 countries, will mark a before and an after within clinical practice. It is a risk indicator that is already a qualitative leap, a cost-effective alternative in front of the existing ones. Now, the next step is to carry out an important information work to show its advantages to all professionals of the industry and to make it useful for improving people life quality.”
Related Links:
Biocross
 Analyzer.jpg)
The risk of developing Alzheimer’s disease (AD) is increased by three to five-folds with the presence of one epsilon4 allele and between 15 and 20 times with two alleles.
The frequency of the epsilon4 allele is approximately 40% in patients with AD. Furthermore, APOEepsilon4 carriers progress faster to clinical AD than do APOEepsilon4 non-carriers. Therefore, the presence of one or two epsilon4 alleles of the APOE gene is considered to be highly informative in epidemiological research and is currently being used for patient stratification in the latest clinical trials to evaluate AD treatments.
The Biocross (Valladolid, Spain) ApoE4 Blood Marker Assay is an immunoturbidimetry-based test. Each assay kit consists of two reagents: R1 (which contains a highly specific anti-apoE4 antibody) and R2 (a solution containing latex (polystyrene beads). During the assay, the anti-apoE4 antibody induces the agglutination of latex beads in the presence of apoE4 in the sample. This agglutination is proportional to the concentration of the apoE4 and can be measured manually or automatically with a spectrophotometer.
The ApoE4 Blood Marker Assay can be used with manageable cost in any of the clinical biochemistry analyzers that are available in most hospitals or clinical centers. The risk indicator is determined by a cost-effective and accurate blood test that is scheduled to obtain the European IVD CE mark and will be submitted for [U.S.] Food and Drug Administration approval by the end of the year.
Matthew Mittino, CEO of Biocross, said, “Introducing our risk test ApoE4 Blood Marker Assay to experts, researchers, physicians, neurologists, and specialists in neurodegenerative diseases from more than 70 countries, will mark a before and an after within clinical practice. It is a risk indicator that is already a qualitative leap, a cost-effective alternative in front of the existing ones. Now, the next step is to carry out an important information work to show its advantages to all professionals of the industry and to make it useful for improving people life quality.”
Related Links:
Biocross
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Gold Member
Hybrid Pipette
SWITCH
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Latest Technology News
- Acoustofluidic Device to Transform Point-Of-Care sEV-Based Diagnostics
- AI Algorithm Assesses Progressive Decline in Kidney Function
- Taste-Based Influenza Test Could Replace Nasal Swabs with Chewing Gum
- 3D Micro-Printed Sensors to Advance On-Chip Biosensing for Early Disease Detection
- Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting
- Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine
- Rapid Diagnostic Technology Utilizes Breath Samples to Detect Lower Respiratory Tract Infections
- Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes
- Wireless Sweat Patch Could Be Used as Diagnostic Test for Cystic Fibrosis
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read more
Hematology
view channel
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more
Platelets Could Improve Early and Minimally Invasive Detection of Cancer
Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more
Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read moreImmunology
view channel
Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more
Luminescent Probe Measures Immune Cell Activity in Real Time
The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more
Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more
Microbiology
view channel
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read more
Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
Sepsis is a life-threatening condition that occurs when the body’s response to infection spirals out of control, damaging organs and leading to critical illness. Patients often arrive at intensive care... Read more
Pathology
view channel
AI Improves Cervical Cancer Screening in Low-Resource Settings
Access to cervical cancer screening in low- and middle-income countries remains limited, leaving many women without early detection for this life-threatening disease. The lack of access to laboratories,... Read more
New Multi-Omics Tool Illuminates Cancer Progression
Tracking how cancers evolve into more aggressive and therapy-resistant forms has long been a challenge for researchers. Many current tools can only capture limited genetic information from tumor samples,... Read more
Technology
view channel
Acoustofluidic Device to Transform Point-Of-Care sEV-Based Diagnostics
Rapid and sensitive detection of small extracellular vesicles (sEVs)—key biomarkers in cancer and organ health monitoring—remains challenging due to the need for multiple preprocessing steps and bulky... Read more
AI Algorithm Assesses Progressive Decline in Kidney Function
Chronic kidney disease (CKD) affects more than 700 million people worldwide and remains a major global health challenge. The condition often progresses silently, and many patients remain undiagnosed until... Read more
Taste-Based Influenza Test Could Replace Nasal Swabs with Chewing Gum
Influenza is one of the most dangerous infectious diseases worldwide, claiming around half a million lives each year. What makes it particularly insidious is that flu viruses are contagious even before... Read more
3D Micro-Printed Sensors to Advance On-Chip Biosensing for Early Disease Detection
Early-stage disease diagnosis depends on the ability to detect biomarkers with exceptional sensitivity and precision. However, traditional biosensing technologies struggle with achieving this at the micro-scale,... Read moreIndustry
view channel
Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
Bio-Rad Laboratories (Hercules, CA, USA) and Biodesix (Louisville, CO, USA) have expanded their partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory... Read more
Hologic to be Acquired by Blackstone and TPG
Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more